文献库，生知库 | 链接生命科学的每一步

日期影响因子

Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination

尼拉帕尼通过抑制IL-17A受体相互作用和促进髓鞘再生，在多发性硬化症中展现出治疗潜力。

期刊:ACS Chemical Neuroscience

影响因子:4.1

doi:10.1021/acschemneuro.5c00519

Muge Didem Orhan ，Lalehan Oktay ，Ayşe Irem Cınar ，Aybek Kagan Yesil ，Huseyin Tunc ，Fatih Eren ，Serdar Durdagi ，Timucin Avsar

多发性硬化症

发表日期：2025

文献求助收藏

Discovering allatostatin type-C receptor specific agonists

发现阿拉托克汀 C 型受体特异性激动剂

期刊:Nature Communications

影响因子:14.7

doi:10.1038/s41467-024-48156-w

Kübra Kahveci, Mustafa Barbaros Düzgün, Abdullah Emre Atis, Abdullah Yılmaz, Aida Shahraki, Basak Coskun, Serdar Durdagi, Necla Birgul Iyison

发表日期：2024

文献求助收藏

Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed

末端炔烃是MAO-A/MAO-B抑制的必要条件吗？一种新的骨架结构被揭示

期刊:Molecules

影响因子:4.6

doi:10.3390/molecules29112486

Mavroeidi, Panagiou; Zorba, Leandros P; Tzouras, Nikolaos V; Neofotistos, Stavros P; Georgiou, Nikitas; Sahin, Kader; Şentürk, Murat; Durdagi, Serdar; Vougioukalakis, Georgios C; Mavromoustakos, Thomas

发表日期：2024

文献求助收藏

Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-Based Classifiers

利用来自广泛配体库的杂原子类型和数量，通过基于机器学习的分类器开发新型hERG阻滞剂QSAR模型

期刊:ACS Omega

影响因子:4.3

doi:10.1021/acsomega.3c06074

Haddad, Safa; Oktay, Lalehan; Erol, Ismail; Şahin, Kader; Durdagi, Serdar

发表日期：2023

文献求助收藏

Prediction of HIV-1 protease resistance using genotypic, phenotypic, and molecular information with artificial neural networks

利用基因型、表型和分子信息，结合人工神经网络预测HIV-1蛋白酶耐药性

影响因子:2.4

doi:10.7717/peerj.14987

Tunc, Huseyin; Dogan, Berna; Darendeli Kiraz, Büşra Nur; Sari, Murat; Durdagi, Serdar; Kotil, Seyfullah

发表日期：2023

文献求助收藏

The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

多尺度计算机模拟和体外实验相结合的研究表明，孟鲁司特对SARS-CoV-2具有中和作用。

期刊:Molecular Therapy

影响因子:12.1

doi:10.1016/j.ymthe.2021.10.014

Serdar Durdagi ,Timucin Avsar ,Muge Didem Orhan ,Muge Serhatli ,Bertan Koray Balcioglu ,Hasan Umit Ozturk ,Alisan Kayabolen ,Yuksel Cetin ,Seyma Aydinlik ,Tugba Bagci-Onder ,Saban Tekin ,Hasan Demirci ,Mustafa Guzel ,Atilla Akdemir ,Seyma Calis ,Lalehan Oktay ,Ilayda Tolu ,Yasar Enes Butun ,Ece Erdemoglu ,Alpsu Olkan ,Nurettin Tokay ,Şeyma Işık ,Aysenur Ozcan ,Elif Acar ,Sehriban Buyukkilic ,Yesim Yumak

发表日期：2022

文献求助收藏

A novel BH3 mimetic Bcl-2 inhibitor promotes autophagic cell death and reduces in vivo Glioblastoma tumor growth

一种新型BH3模拟物Bcl-2抑制剂可促进自噬性细胞死亡并减少体内胶质母细胞瘤的生长

期刊:Cell Death Discovery

影响因子:6.1

doi:10.1038/s41420-022-01225-9

Seyma Calis ，Berna Dogan ，Serdar Durdagi ，Asuman Celebi ，Ozlem Yapicier ，Turker Kilic ，Eda Tahir Turanli ，Timucin Avsar

细胞生物学

发表日期：2022

文献求助收藏

Mechanistic insight into the impact of a bivalent ligand on the structure and dynamics of a GPCR oligomer

从机制上深入了解二价配体对GPCR寡聚体结构和动力学的影响

期刊:Computational and Structural Biotechnology Journal

影响因子:4.1

doi:10.1016/j.csbj.2022.01.016

Mansoor, Samman; Kayık, Gülru; Durdagi, Serdar; Sensoy, Ozge

GPCR/Calcium/cAMP

发表日期：2022

文献求助收藏

Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy

新型依托度酸衍生物作为真核延伸因子2激酶（eEF2K）抑制剂用于靶向癌症治疗

期刊:RSC Medicinal Chemistry

影响因子:3.6

doi:10.1039/d2md00105e

Comert Onder, Ferah; Siyah, Pinar; Durdagi, Serdar; Ay, Mehmet; Ozpolat, Bulent

发表日期：2022

文献求助收藏

Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study

筛选已获临床批准和在研药物作为SARS-CoV-2潜在抑制剂：一项结合计算机模拟和体外实验的研究

期刊:Molecular Informatics

影响因子:3.1

doi:10.1002/minf.202100062

Durdagi, Serdar; Orhan, Muge Didem; Aksoydan, Busecan; Calis, Seyma; Dogan, Berna; Sahin, Kader; Shahraki, Aida; Iyison, Necla Birgül; Avsar, Timucin

发表日期：2022

文献求助收藏